Table 1 Patient demographics and clinical characteristics
Demographics or clinical characteristics | Cis/carboplatin and pemetrexed (n = 116) | Cis/carboplatin and gemcitabine (n = 30) | p value |
|---|---|---|---|
Mean age, years | 60.7 ± 10.9 | 60.8 ± 9.9 | 0.945 |
Male: Female | 58 : 58 | 14 : 16 | 0.745 |
Asbestos exposure, n (%) | 113 (97.4) | 29 (96.7) | 0.827 |
Mean Karnofsky Performance Status | 85.7 ± 9.9 | 80.3 ± 8.7 | 0.062 |
Histology, n (%) | |||
Epithelial | 92 (79.3) | 22 (73.3) | 1.00 |
Sarcomatous | 9 (7.8) | 2 (6.7) | |
Mixed | 12 (10.3) | 5 (16.7) | |
Unidentified | 3 (2.6) | 1 (3.3) | |
Stage, n (%) | |||
I | 6 (5.2) | 2 (6.7) | 0.662 |
II | 12 (10.4) | 2 (6.7) | |
III | 41 (35.7) | 14 (46.7) | |
IV | 56 (48.7) | 12 (40.0) | |
Pleurodesis, n (%) | 41 (35.3) | 10 (33.3) | 0.837 |
Prophylactic radiotherapy, n (%) | 22 (19.0) | 2 (6.7) | 0.083 |
Second–line chemotherapy, n (%) | 36 (31.0) | 8 (26.7) | 0.642 |
Median baseline hemoglobin, g / dL | 12.5 | 12.3 | 0.679 |
Median baseline serum albumin, g / dL | 3.8 | 3.6 | 0.336 |